» Articles » PMID: 17699268

Medical Care of Kidney Transplant Recipients After the First Posttransplant Year

Overview
Specialty Nephrology
Date 2007 Aug 21
PMID 17699268
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Kidney transplantation is the treatment of choice for patients with ESRD. Despite improvements in short-term patient and graft outcomes, there has been no major improvement in long-term outcomes. The use of kidney allografts from expanded-criteria donors, polyoma virus nephropathy, underimmunosuppression, and incomplete functional recovery after rejection episodes may play a role in the lack of improvement in long-term outcomes. Other factors, including cardiovascular disease, infections, and malignancies, also shorten patient survival and therefore reduce the functional life of an allograft. There is a need for interventions that improve long-term outcomes in kidney transplant recipients. These patients are a unique subset of patients with chronic kidney disease. Therefore, interventions need to address disease progression, comorbid conditions, and patient mortality through a multifaceted approach. The Kidney Disease Outcomes Quality Initiative from the National Kidney Foundation, the European Best Practice Guidelines, and the forthcoming Kidney Disease: Improving Global Outcomes clinical practice guidelines can serve as a cornerstone of this approach. The unique aspects of chronic kidney disease in the transplant recipient require the integration of specific transplant-oriented problems into this care schema and a concrete partnership among transplant centers, community nephrologists, and primary care physicians. This article reviews the contemporary aspects of care for these patients.

Citing Articles

Post-transplant renal anemia: a call to action from a national study in routine clinical practice.

Portoles J, Crespo M, Martinez Belotto M, Martinez Morales E, Calatayud Aristoy E, Mora Lopez P Clin Kidney J. 2024; 17(10):sfae269.

PMID: 39372236 PMC: 11450472. DOI: 10.1093/ckj/sfae269.


Impact of IL-6 and IL-10 genotypes on tacrolimus dose requirements in kidney transplant recipients: Monte Carlo analysis.

Stefanovic N, Dankovic K, Cvetkovic T, Vujic S, Pavlovic I, Jevtovic-Stoimenov T Pharmacogenomics. 2024; 25(7):315-327.

PMID: 39069949 PMC: 11404698. DOI: 10.1080/14622416.2024.2379227.


Long-term effects of average calcineurin inhibitor trough levels (over time) on renal function in a prospectively followed cohort of 150 kidney transplant recipients.

Ciancio G, Gaynor J, Guerra G, Tabbara M, Roth D, Kupin W Clin Transl Sci. 2023; 16(11):2382-2393.

PMID: 37817405 PMC: 10651634. DOI: 10.1111/cts.13639.


Incidence and Causes of Early Hospital Readmissions After Living-Donor Renal Transplant at King Abdulaziz Medical City, Riyadh.

Altamimi A, Alrzouq F, Aljaafri Z, Alahmadi F, Alsuwailem Y, Dendini F Cureus. 2023; 15(6):e40254.

PMID: 37440811 PMC: 10335600. DOI: 10.7759/cureus.40254.


Determinants of hyperphosphatemia and its relation with hemoglobin levels among hemodialysis patients in two hospitals from Syria: a prospective cross-sectional study.

Alsultan M, Kliea M, Anan M, Abdulkader B, Kazkaz R, Al Sultan A Ann Med Surg (Lond). 2023; 85(6):2451-2458.

PMID: 37363538 PMC: 10289654. DOI: 10.1097/MS9.0000000000000632.